Cannabinoid Hyperemesis Syndrome: A Case Report and Discussion Regarding Patients with Concurrent Disorders.

In October 2018, Canada legalized the nonmedical use of cannabis. Usage has traditionally been high in Canada, and after legalization, self-reported use increased from 14% to 18%.1 Given this increased usage, it is important to understand the adverse effects of cannabis. Here, we focus on a less well-recognized consequence, cannabinoid hyperemesis syndrome (CHS), first described in 2004.2 It may be seen more often in jurisdictions where cannabis is legalized; for example, from 2009 to 2011, after legalization of cannabis in the state of Colorado, presentations to emergency departments for CHS increased by almost 100%.3 CHS presents similarly to cyclic vomiting syndrome, with recurrent nausea and vomiting episodes interspersed with asymptomatic periods.4 However, several features differentiate CHS from cyclic vomiting syndrome. CHS is associated with a history of chronic cannabis use, cure of the syndrome after cessation of cannabis, and delayed gastric emptying.4 Cyclic vomiting syndrome is often associated with concurrent migraines and psychiatric conditions, as well as rapid gastric emptying.4 The prodromal phase lasts up to several years in CHS,4 but just minutes to hours in cyclic vomiting syndrome.5 The following characteristics seem to have the highest sensitivity for diagnosis of CHS: weekly cannabis use for more than 1 year, severe nausea and vomiting with abdominal pain repeating in a cyclic pattern over months, resolution of symptoms after cannabis cessation, and compulsive use of hot baths or showers to provide temporary symptom relief.6 Normal bowel habits are cited as supportive criteria. However, abnormal bowel habits do not necessarily rule out CHS, as there are a number of recorded cases, including the patient described in this report, with both CHS and abnormal bowel habits.7 The complications of CHS, which are due to recurrent vomiting, include fluid and electrolyte disorders, nutritional deficiencies, aspiration, pneumonitis, and esophageal wall injury.8 Unfortunately, given that CHS is poorly recognized, patients often undergo potentially harmful procedures such as radiography, computed tomography (CT), endoscopy, and appendectomy in search of a diagnosis.4 Here, we describe CHS by means of a clinical case and then discuss the challenges that may be encountered within the subpopulation of patients with concurrent disorders.

[1]  M. Rotermann Analysis of trends in the prevalence of cannabis use and related metrics in Canada. , 2019, Health reports.

[2]  D. Abrams Should Oncologists Recommend Cannabis? , 2019, Current Treatment Options in Oncology.

[3]  D. Levinthal,et al.  Guidelines on management of cyclic vomiting syndrome in adults by the American Neurogastroenterology and Motility Society and the Cyclic Vomiting Syndrome Association , 2019, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[4]  Gang Wang,et al.  Lifestyle intervention for gastroesophageal reflux disease: a national multicenter survey of lifestyle factor effects on gastroesophageal reflux disease in China , 2019, Therapeutic advances in gastroenterology.

[5]  John A. Kappes,et al.  Cyclic vomiting syndrome: diagnostic approach and current management strategies , 2018, Clinical and experimental gastroenterology.

[6]  C. Kahn,et al.  Cannabinoid Hyperemesis Syndrome: Public Health Implications and a Novel Model Treatment Guideline , 2017, The western journal of emergency medicine.

[7]  O. Amaral,et al.  Living Conditions and Helicobacter pylori in Adults , 2017, BioMed research international.

[8]  J. Richards,et al.  Pharmacologic Treatment of Cannabinoid Hyperemesis Syndrome: A Systematic Review , 2017, Pharmacotherapy.

[9]  N. Ewald,et al.  Cannabinoid hyperemesis and the cyclic vomiting syndrome in adults: recognition, diagnosis, acute and long-term treatment , 2017, German medical science : GMS e-journal.

[10]  A. Monte,et al.  Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment—a Systematic Review , 2017, Journal of Medical Toxicology.

[11]  Vinesh G. Narayan,et al.  Lifestyle factors and the metabolic syndrome in Schizophrenia: a cross-sectional study , 2017, Annals of General Psychiatry.

[12]  J. Siple,et al.  Cannabinoid Hyperemesis Syndrome , 2016, The Annals of pharmacotherapy.

[13]  Howard S. Kim,et al.  Cyclic vomiting presentations following marijuana liberalization in Colorado. , 2015, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[14]  R. Griffiths,et al.  Caffeine Use Disorder: A Comprehensive Review and Research Agenda. , 2013, Journal of caffeine research.

[15]  Jason H. Szostek,et al.  Cannabinoid hyperemesis: a case series of 98 patients. , 2011, Mayo Clinic proceedings.

[16]  R. Heddle,et al.  Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse , 2004, Gut.

[17]  J. Greden,et al.  Anxiety and depression associated with caffeinism among psychiatric inpatients. , 1978, The American journal of psychiatry.

[18]  '. D.M.ROBERTS Chronic gastritis, alcohol, and non-ulcer dyspepsia' , 2006 .